Seer Board Reviews Competing Takeover Bids from Activists and Its Own CEO
Seer confirms two revised unsolicited offers: $2.55 + CVR from Radoff-JEC Group and $2.45 + two CVRs from CEO Farokhzad. Special committee reviewing.
/ 492 items
#XY Event-Driven Stocks↓
Abivax Gets Positive FDA Feedback, Stays on Track to File for New Ulcerative Colitis Drug by End of 2026
Abivax completes positive pre-NDA meeting with FDA for obefazimod in ulcerative colitis, stays on track for 2026 filing, with $3-5B peak sales potential.
FDA Panel Backs Replimune’s Melanoma Drug After Multiple Rejections
FDA panel votes 10-3 for Replimune’s RP1 melanoma drug after two rejections, citing benefits for resistant patients despite messy data.
Karyopharm Shares Plunge After Selinexor Misses in Endometrial Cancer Trial
Karyopharm seeks accelerated FDA approval for selinexor combined with ruxolitinib—the potential first novel combo therapy for myelofibrosis patients.
Johnson & Johnson Cuts 2026 Earnings Outlook on $1 Billion Acquisition Costs
Johnson & Johnson cuts 2026 adjusted EPS guidance to $10.96–$11.11 after its $1B Firefly Bio acquisition and Sail Biomedicines partnership.
MiMedx Buys Sanara MedTech to Nearly Double Surgical Revenue
MiMedx agrees to buy Sanara MedTech for $35/share in a $350M cash-and-stock deal to nearly double surgical revenue. 2027 sales seen over $400M.